DOCSLIB.ORG

Conotoxin MII-Sensitive Nicotinic Acetylcholine Receptors in the Nucleus Accumbens Shell Regulate Progressive Ratio Responding Maintained by Nicotine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Conotoxin MII-Sensitive Nicotinic Acetylcholine Receptors in the Nucleus Accumbens Shell Regulate Progressive Ratio Responding Maintained by Nicotine Neuropsychopharmacology (2010) 35, 665–673 & 2010 Nature Publishing Group All rights reserved 0893-133X/10 $32.00 www.neuropsychopharmacology.org a-Conotoxin MII-Sensitive Nicotinic Acetylcholine Receptors in the Nucleus Accumbens Shell Regulate Progressive Ratio Responding Maintained by Nicotine ,1 1 1 1 Darlene H Brunzell* , Karen E Boschen , Elizabeth S Hendrick , Patrick M Beardsley and 2,3 J Michael McIntosh 1 2 Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA; Department of Psychiatry, University of 3 Utah, Salt Lake City, UT, USA; Department of Biology, University of Utah, Salt Lake City, UT, USA b2 subunit containing nicotinic acetylcholine receptors (b2*nAChRs; asterisk (*) denotes assembly with other subunits) are critical for nicotine self-administration and nicotine-associated dopamine (DA) release that supports nicotine reinforcement. The a6 subunit assembles with b2 on DA neurons where a6b2*nAChRs regulate nicotine-stimulated DA release at neuron terminals. Using local infusion of a-conotoxin MII (a-CTX MII), an antagonist with selectivity for a6b2*nAChRs, the purpose of these experiments was to determine if a6b2*nAChRs in the nucleus accumbens (NAc) shell are required for motivation to self-administer nicotine. Long-Evans rats lever-pressed for 0.03 mg/kg, i.v., nicotine accompanied by light + tone cues (NIC) or for light + tone cues unaccompanied by nicotine (CUEonly). Following extensive training, animals were tested under a progressive ratio (PR) schedule that required an increasing number of lever presses for each nicotine infusion and/or cue delivery. Immediately before each PR session, rats received microinfusions of a-CTX MII (0, 1, 5, or 10 pmol per side) into the NAc shell or the overlying anterior cingulate cortex. a-CTX MII dose dependently decreased break points and number of infusions earned by NIC rats following infusion into the NAc shell but not the anterior cingulate a cortex. Concentrations of -CTX MII that were capable of attenuating nicotine self-administration did not disrupt locomotor activity. There was no effect of infusion on lever pressing in CUEonly animals and NAc infusion a-CTX MII did not affect locomotor activity in an open field. These data suggest that a6b2*nAChRs in the NAc shell regulate motivational aspects of nicotine reinforcement but not nicotine-associated locomotor activation. Neuropsychopharmacology (2010) 35, 665–673; doi:10.1038/npp.2009.171; published online 4 November 2009 Keywords: a6; a3; motivation; reward; locomotor activation; tobacco INTRODUCTION self-administration (Corrigall et al, 1992), suggesting that these DA inputs are critical for nicotine reinforcement. Cigarette smoking is the leading preventable cause of death An accumulation of transgenic and neurochemical data in developed countries and is a growing health problem suggests that nicotine-associated DA release and nicotine worldwide (WHO, 2008). Nicotine, the major psychoactive reinforcement are regulated by nicotinic receptors that ingredient in tobacco, and cigarette-associated cues result contain the b2 nicotinic acetylcholine receptor subunit in mesolimblic dopamine (DA) release from the ventral (b2*nAChR; asterisk (*) denotes assembly with other tegmental area (VTA) and activation of VTA projection subunits) (Corrigall et al, 1994; Picciotto et al, 1998; regions including the anterior cingulate cortex and the Champtiaux et al, 2003; Salminen et al, 2004, 2007; Tapper nucleus accumbens (NAc), brain areas associated with the et al, 2004; Maskos et al, 2005; Drenan et al, 2008; Pons et al, rewarding effects of nicotine in smokers (Stein et al, 1998; 2008), making these receptors an attractive therapeutic Schroeder et al, 2001; Due et al, 2002; Volkow et al, 2007). target for tobacco cessation (Gonzales et al, 2006; Rollema Lesions of DA projections to the NAc attenuate nicotine et al, 2007). b2*nAChRs, however, have a ubiquitous expression pattern and contribute more generally to moti- vation, mood, and cognition (for review, see Levin et al, 2006; Brunzell and Picciotto, 2009). Because b2*nAChRs *Correspondence: Dr DH Brunzell, Department of Pharmacology, Virginia Commonwealth University, 410 N 12th Street, PO Box are also very diverse in their composition, identification 980613, Richmond, VA 23298, USA, Tel: + 1 804 628 7584, of receptor subunits that assemble with b2 but that Fax: + 1 804 828 2117, E-mail: [email protected] have a more selective expression pattern may lead to Received 8 July 2009; revised 5 September 2009; accepted 27 tobacco cessation compounds with less potential for side September 2009 effects. a6b2*nAChRs support motivation for nicotine use DH Brunzell et al 666 The a6 nAChR subunit assembles with b2 but is MATERIALS AND METHODS selectively expressed in catecholaminergic nuclei and on terminals in catecholaminergic projection areas (Le Novere Animals et al, 1996; Klink et al, 2001). b2*nAChRs can be classified Twenty-eight adult, male, Long-Evans rats (Harlan Labora- according to their sensitivity to the cone snail toxin, tories, Dublin, VA), weighing approximately 300 g on a-conotoxin MII (a-CTX MII). Synaptosome studies using arrival, were used for these studies. Rats were individually a combination of knockout technology and nicotinic housed in a temperature- and humidity-controlled environ- antagonism with the a-CTX MII peptide indicate that ment with a 12:12 h light/dark cycle (lights on 0600 hours). a6b2*nAChRs on striatal DA terminals participate in Animals began testing at 320 g; animals were nutritionally nicotine-stimulated DA release (Champtiaux et al, 2003; maintained at this body weight by daily food rations Salminen et al, 2004, 2007). Both a3b2* and a6b2* nAChRs throughout behavioral testing (Christian et al, 1998). The are highly sensitive to a-CTX MII antagonism (Cartier experimental protocol was approved by the Institutional et al, 1996; Kuryatov et al, 2000; McIntosh et al, 2004), but Animal Care and Use Committee at Virginia Common- expression of the a6 subunit greatly predominates in the wealth University, and all animals were treated according to VTA and NAc, where the a3 subunit is essentially absent the Guidelines for the Care and Use of Laboratory Animals, (Champtiaux et al, 2002; Whiteaker et al, 2002; Salminen as set forth by the National Institutes of Health. et al, 2005). A recent report by Drenan et al (2008) showed that a single-point mutation in the pore-forming region of Drug Dosing and Administration the a6 subunit, which renders a6b2*nAChRs hypersensitive to nicotine, led to nicotine-associated stimulation of During self-administration procedures, rats received VTA DA neurons and locomotor activation at otherwise 0.03 mg/kg, i.v., infusion of nicotine (by weight of freebase) subthreshold levels of nicotine; these data suggest that in 0.0533 ml delivered over 1 s. Nicotine hydrogen tartrate activation of a6b2*nAChRs are sufficient for DA-stimulat- salt was dissolved in 0.9% sterile saline and stored in ing effects of nicotine. In addition, nicotine self-adminis- the dark to prevent degradation. a-CTX MII was synthe- tration is absent in a6 subunit null mutant mice but sized as previously described (Cartier et al, 1996) and lentiviral rescue of a6 subunit mRNA in the VTA region of dissolved in 0.9% sterile saline. Aliquots were stored at À201C until used for experimentation and were kept these animals leads to recovery of nicotine self-administra- 1 tion in an acute, single-day, tail-vein procedure (Pons et al, at 4 C no longer than 1 week after thawing. Animals 2008). Together these studies suggest that a6b2*nAChRs received 0.5–1 ml intra-accumbens shell infusions of 0, 1, 5, on mesolimblic DA neurons regulate DA release and or 10 pmol per side of a-CTX MII. For locomotor studies, nicotine reward; however, the neuroanatomical locus where rats received s.c. injections of 0.175 mg/kg nicotine (by a6b2*nAChRs exert their effects on nicotine reinforcement weight of freebase) at a concentration of 2.0 mg/ml in sterile and locomotor activation is unclear. In addition, although saline. the tail-vein self-administration paradigm suggests that a b 6 2*nAChRs in the VTA and/or VTA projection areas Intra-Jugular Catheter Implantation may be critical for initiation of tobacco use, less is known regarding the role of these receptors in nicotine reinforce- All surgeries were performed using aseptic procedures. ment following repeated nicotine exposure. The current Anesthesia was induced with 3.5% isoflurane gas at 3.5 liter/ studies used a more sustained nicotine self-administration min oxygen and maintained at 2.0% isoflurane and 2.5 liter/ paradigm in rats. Following training under a fixed ratio min of oxygen. Surgical areas were shaved and cleaned with (FR) schedule of reinforcement, animals were switched 7.5% povidone–iodine and 70% reagent alcohol. A tapered to a progressive ratio (PR) schedule of reinforcement in polyurethane catheter (3.5 French; Access Technologies) was which rats were required to emit an increasing number implanted in the right jugular vein above the atrium. of responses for a single i.v. infusion of nicotine accom- Following implantation, the catheter was passed subcuta- panied by light and tone cues (NIC). To determine if neously to the rat’s back and connected to a back-mounted MII-sensitive nAChRs on terminals in the NAc shell and pedestal (Plastics One, Roanoke, VA). To prevent infection, anterior cingulate cortex regulate motivation for nicotine all rats received s.c. injection of 75 000 U penicillin G and and nicotine-associated cues, we used local infusions 0.1 ml intracatheter injection of 0.031 mg/ml ticarcillin/ of a-CTX MII to block a6b2*nAChRs in these DA projection clavulanate in 25% glycerol/heparinized saline (catheter lock). areas immediately before PR testing. Control animals During surgery, rats received 5 mg/kg, i.p., carprofen for lever-pressed for the same cues as nicotine subjects, but preemptive analgesia. Rats also received 64 mg acetamino- the cues were unaccompanied by nicotine (CUEonly).
Load more

Recommended publications
  • Interactions of Insecticidal Spider Peptide Neurotoxins with Insect Voltage- and Neurotransmitter-Gated Ion Channels
    Interactions of insecticidal spider peptide neurotoxins with insect voltage- and neurotransmitter-gated ion channels (Molecular representation of - HXTX-Hv1c including key binding residues, adapted from Gunning et al, 2008) PhD Thesis Monique J. Windley UTS 2012 CERTIFICATE OF AUTHORSHIP/ORIGINALITY I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as fully acknowledged within the text. I also certify that the thesis has been written by me. Any help that I have received in my research work and the preparation of the thesis itself has been acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis. Monique J. Windley 2012 ii ACKNOWLEDGEMENTS There are many people who I would like to thank for contributions made towards the completion of this thesis. Firstly, I would like to thank my supervisor Prof. Graham Nicholson for his guidance and persistence throughout this project. I would like to acknowledge his invaluable advice, encouragement and his neverending determination to find a solution to any problem. He has been a valuable mentor and has contributed immensely to the success of this project. Next I would like to thank everyone at UTS who assisted in the advancement of this research. Firstly, I would like to acknowledge Phil Laurance for his assistance in the repair and modification of laboratory equipment. To all the laboratory and technical staff, particulary Harry Simpson and Stan Yiu for the restoration and sourcing of equipment - thankyou. I would like to thank Dr Mike Johnson for his continual assistance, advice and cheerful disposition.
    [Show full text]
  • Slow Inactivation in Voltage Gated Potassium Channels Is Insensitive to the Binding of Pore Occluding Peptide Toxins
    Biophysical Journal Volume 89 August 2005 1009–1019 1009 Slow Inactivation in Voltage Gated Potassium Channels Is Insensitive to the Binding of Pore Occluding Peptide Toxins Carolina Oliva, Vivian Gonza´lez, and David Naranjo Centro de Neurociencias de Valparaı´so, Facultad de Ciencias, Universidad de Valparaı´so, Valparaı´so, Chile ABSTRACT Voltage gated potassium channels open and inactivate in response to changes of the voltage across the membrane. After removal of the fast N-type inactivation, voltage gated Shaker K-channels (Shaker-IR) are still able to inactivate through a poorly understood closure of the ion conduction pore. This, usually slower, inactivation shares with binding of pore occluding peptide toxin two important features: i), both are sensitive to the occupancy of the pore by permeant ions or tetraethylammonium, and ii), both are critically affected by point mutations in the external vestibule. Thus, mutual interference between these two processes is expected. To explore the extent of the conformational change involved in Shaker slow inactivation, we estimated the energetic impact of such interference. We used kÿconotoxin-PVIIA (kÿPVIIA) and charybdotoxin (CTX) peptides that occlude the pore of Shaker K-channels with a simple 1:1 stoichiometry and with kinetics 100-fold faster than that of slow inactivation. Because inactivation appears functionally different between outside-out patches and whole oocytes, we also compared the toxin effect on inactivation with these two techniques. Surprisingly, the rate of macroscopic inactivation and the rate of recovery, regardless of the technique used, were toxin insensitive. We also found that the fraction of inactivated channels at equilibrium remained unchanged at saturating kÿPVIIA.
    [Show full text]
  • Conotoxins That Could Provide Analgesia Through Voltage Gated Sodium Channel Inhibition
    Review Conotoxins That Could Provide Analgesia through Voltage Gated Sodium Channel Inhibition Nehan R. Munasinghe and MacDonald J. Christie * Received: 14 August 2015; Accepted: 19 November 2015; Published: 10 December 2015 Academic Editor: Luis Botana Discipline of Pharmacology, The University of Sydney, Sydney, NSW 2006, Australia; [email protected] * Correspondence: [email protected]; Tel.: +61-2-9351-2946; Fax: +61-2-9351-3868 Abstract: Chronic pain creates a large socio-economic burden around the world. It is physically and mentally debilitating, and many suffers are unresponsive to current therapeutics. Many drugs that provide pain relief have adverse side effects and addiction liabilities. Therefore, a great need has risen for alternative treatment strategies. One rich source of potential analgesic compounds that has immerged over the past few decades are conotoxins. These toxins are extremely diverse and display selective activity at ion channels. Voltage gated sodium (NaV) channels are one such group of ion channels that play a significant role in multiple pain pathways. This review will explore the literature around conotoxins that bind NaV channels and determine their analgesic potential. Keywords: conotoxins; toxins; NaV; ion channels; pain; analgesia; inhibition 1. Introduction Chronic pain is a major problem in the world today. The total cost of chronic pain in the United States was estimated to be between $560 and $635 billion per annum [1]. This cost is greater than cancer and heart diseases combined [1]. The current therapeutics that are available for chronic pain often provide only limited pain relief and have many side effects. Therefore, there is a great need for alternative therapies that provide analgesia to chronic pain sufferers.
    [Show full text]
  • NIH Public Access Author Manuscript Eur J Pharmacol
    NIH Public Access Author Manuscript Eur J Pharmacol. Author manuscript; available in PMC 2012 November 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Eur J Pharmacol. 2011 November 1; 669(1-3): 71±75. doi:10.1016/j.ejphar.2011.08.001. Brain regions mediating α3β4 nicotinic antagonist effects of 18- MC on nicotine self-administration Stanley D. Glick, Elizabeth M. Sell, Sarah E McCallum, and Isabelle M. Maisonneuve Center for Neuropharmacology and Neuroscience, Albany Medical College (MC-136), 47 New Scotland Avenue, Albany, NY 12208, USA Abstract 18-methoxycoronaridine (18-MC), a putative anti-addictive agent, has been shown to decrease the self-administration of several drugs of abuse in rats. 18-MC is a potent antagonist at α3β4 nicotinic receptors. Consistent with high densities of α3β4 nicotinic receptors being located in the medial habenula and the interpeduncular nucleus, 18-MC has been shown to act in these regions to decrease both morphine and methamphetamine self-administration. The present study was conducted to determine if 18-MC’s effect on nicotine self-administration is mediated by acting in these same brain regions. Because moderate densities of α3β4 receptors occur in the dorsolateral tegmentum, ventral tegmental area, and basolateral amygdala, these brain areas were also examined as potential sites of action of 18-MC. Local administration of 18-MC into either the medial habenula, the basolateral amygdala or the dorsolateral tegmentum decreased nicotine self- administration. Surprisingly, local administration of 18-MC into the interpeduncular nucleus increased nicotine self-administration while local administration of 18-MC into the ventral tegmental area had no effect on nicotine self-administration.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Characterisation of a Novel A-Superfamily Conotoxin
    biomedicines Article Characterisation of a Novel A-Superfamily Conotoxin David T. Wilson 1, Paramjit S. Bansal 1, David A. Carter 2, Irina Vetter 2,3, Annette Nicke 4, Sébastien Dutertre 5 and Norelle L. Daly 1,* 1 Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Smithfield, QLD 4878, Australia; [email protected] (D.T.W.); [email protected] (P.S.B.) 2 Centre for Pain Research, Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia; [email protected] (D.A.C.); [email protected] (I.V.) 3 School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, Australia 4 Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, LMU Munich, Nußbaumstraße 26, 80336 Munich, Germany; [email protected] 5 Institut des Biomolécules Max Mousseron, UMR 5247, Université de Montpellier, CNRS, 34095 Montpellier, France; [email protected] * Correspondence: [email protected]; Tel.: +61-7-4232-1815 Received: 3 May 2020; Accepted: 18 May 2020; Published: 20 May 2020 Abstract: Conopeptides belonging to the A-superfamily from the venomous molluscs, Conus, are typically α-conotoxins. The α-conotoxins are of interest as therapeutic leads and pharmacological tools due to their selectivity and potency at nicotinic acetylcholine receptor (nAChR) subtypes. Structurally, the α-conotoxins have a consensus fold containing two conserved disulfide bonds that define the two-loop framework and brace a helical region. Here we report on a novel α-conotoxin Pl168, identified from the transcriptome of Conus planorbis, which has an unusual 4/8 loop framework.
    [Show full text]
  • Conotoxins As Tools to Understand the Physiological Function of Voltage-Gated Calcium (Cav) Channels
    marine drugs Review Conotoxins as Tools to Understand the Physiological Function of Voltage-Gated Calcium (CaV) Channels David Ramírez 1,2, Wendy Gonzalez 1,3, Rafael A. Fissore 4 and Ingrid Carvacho 5,* 1 Centro de Bioinformática y Simulación Molecular, Universidad de Talca, 3460000 Talca, Chile; [email protected] (D.R.); [email protected] (W.G.) 2 Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, 3460000 Talca, Chile 3 Millennium Nucleus of Ion Channels-Associated Diseases (MiNICAD), Universidad de Talca, 3460000 Talca, Chile 4 Department of Veterinary and Animal Sciences, University of Massachusetts, Amherst, MA 01003, USA; rfi[email protected] 5 Department of Biology and Chemistry, Faculty of Basic Sciences, Universidad Católica del Maule, 3480112 Talca, Chile * Correspondence: [email protected]; Tel.: +56-71-220-3518 Received: 8 August 2017; Accepted: 4 October 2017; Published: 13 October 2017 Abstract: Voltage-gated calcium (CaV) channels are widely expressed and are essential for the completion of multiple physiological processes. Close regulation of their activity by specific inhibitors and agonists become fundamental to understand their role in cellular homeostasis as well as in human tissues and organs. CaV channels are divided into two groups depending on the membrane potential required to activate them: High-voltage activated (HVA, CaV1.1–1.4; CaV2.1–2.3) and Low-voltage activated (LVA, CaV3.1–3.3). HVA channels are highly expressed in brain (neurons), heart, and adrenal medulla (chromaffin cells), among others, and are also classified into subtypes which can be distinguished using pharmacological approaches. Cone snails are marine gastropods that capture their prey by injecting venom, “conopeptides”, which cause paralysis in a few seconds.
    [Show full text]
  • Voltage-Gated Sodium Channels and Blockers: an Overview and Where Will They Go?*
    Current Medical Science 39(6):863-873,2019 DOICurrent https://doi.org/10.1007/s11596-019-2117-0 Medical Science 39(6):2019 863 Voltage-gated Sodium Channels and Blockers: An Overview and Where Will They Go?* Zhi-mei LI1, Li-xia CHEN2#, Hua LI1# 1Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China 2Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China Huazhong University of Science and Technology 2019 Summary: Voltage-gated sodium (Nav) channels are critical players in the generation and propagation of action potentials by triggering membrane depolarization. Mutations in Nav channels are associated with a variety of channelopathies, which makes them relevant targets for pharmaceutical intervention. So far, the cryoelectron microscopic structure of the human Nav1.2, Nav1.4, and Nav1.7 has been reported, which sheds light on the molecular basis of functional mechanism of Nav channels and provides a path toward structure-based drug discovery. In this review, we focus on the recent advances in the structure, molecular mechanism and modulation of Nav channels, and state updated sodium channel blockers for the treatment of pathophysiology disorders and briefly discuss where the blockers may be developed in the future. Key words: voltage-gated sodium channels; blockers; Nav channel structures; channelopathies Life did not come into existence until living In this review, we focus on voltage-gated organisms were enclosed by one or more membranes sodium (Nav) channels, which selectively conduct which cut them off from the chaotic world at a sodium ions movement in response to variations of molecular level.
    [Show full text]
  • Centipede Venoms As a Source of Drug Leads
    Title Centipede venoms as a source of drug leads Authors Undheim, EAB; Jenner, RA; King, GF Description peerreview_statement: The publishing and review policy for this title is described in its Aims & Scope. aims_and_scope_url: http://www.tandfonline.com/action/journalInformation? show=aimsScope&journalCode=iedc20 Date Submitted 2016-12-14 Centipede venoms as a source of drug leads Eivind A.B. Undheim1,2, Ronald A. Jenner3, and Glenn F. King1,* 1Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia 2Centre for Advanced Imaging, The University of Queensland, St Lucia, QLD 4072, Australia 3Department of Life Sciences, Natural History Museum, London SW7 5BD, UK Main text: 4132 words Expert Opinion: 538 words References: 100 *Address for correspondence: [email protected] (Phone: +61 7 3346-2025) 1 Centipede venoms as a source of drug leads ABSTRACT Introduction: Centipedes are one of the oldest and most successful lineages of venomous terrestrial predators. Despite their use for centuries in traditional medicine, centipede venoms remain poorly studied. However, recent work indicates that centipede venoms are highly complex chemical arsenals that are rich in disulfide-constrained peptides that have novel pharmacology and three-dimensional structure. Areas covered: This review summarizes what is currently know about centipede venom proteins, with a focus on disulfide-rich peptides that have novel or unexpected pharmacology that might be useful from a therapeutic perspective. We also highlight the remarkable diversity of constrained three- dimensional peptide scaffolds present in these venoms that might be useful for bioengineering of drug leads. Expert opinion: The resurgence of interest in peptide drugs has stimulated interest in venoms as a source of highly stable, disulfide-constrained peptides with potential as therapeutics.
    [Show full text]
  • Biological Agent Reference Sheet (BARS)- Conotoxin
    Biological Agent Reference Sheet (BARS) This content of this document is for Emory University USE ONLY. The information and contents of this Biological Agent Reference Sheet (including all text and graphics), whether available in print or electronic format (including any digital format, e-mail transmissions, or download from the website), shall be known hereinafter as “Reference Sheet Content”. The Reference Sheet Content is provided as a courtesy and is not intended as a sole source of guidance in the evaluation of Biological Agents. The Reference Sheet Content is not intended to substitute for medical advice, medical care, diagnosis or treatment obtained from a physician or health care provider. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not rely on the Reference Sheet Content for diagnosis, treatment, or medical advice. This Reference Sheet Content is for informational purposes and does not provide individualized medical care or treatment. No endorsement of any specific tests, products, or procedures is made by Reference Sheet Content or affiliated party, member, agent or employee of the Emory University Environmental Health and Safety Office. 1762 Clifton Road, Suite 1200 Atlanta, Georgia 30322 (404) 727-5922 FAX: (404) 727-9778 BIOLOGICAL AGENT REFERENCE SHEET Conotoxin CHARACTERISTICS SPILL PROCEDURES Neurotoxic venom naturally produced by the Conus Notify others working in the lab. Rinse gloves with Natural Source genus of gastropod mollusks decontamination solution and don new gloves. Laboratory Cover area of the spill with paper towels and apply Isolated toxin Source decontamination solution, working from the Conotoxins are polypeptides comprised of 10-30 Small perimeter towards the center.
    [Show full text]
  • Botulinum Toxin
    Botulinum toxin From Wikipedia, the free encyclopedia Jump to: navigation, search Botulinum toxin Clinical data Pregnancy ? cat. Legal status Rx-Only (US) Routes IM (approved),SC, intradermal, into glands Identifiers CAS number 93384-43-1 = ATC code M03AX01 PubChem CID 5485225 DrugBank DB00042 Chemical data Formula C6760H10447N1743O2010S32 Mol. mass 149.322,3223 kDa (what is this?) (verify) Bontoxilysin Identifiers EC number 3.4.24.69 Databases IntEnz IntEnz view BRENDA BRENDA entry ExPASy NiceZyme view KEGG KEGG entry MetaCyc metabolic pathway PRIAM profile PDB structures RCSB PDB PDBe PDBsum Gene Ontology AmiGO / EGO [show]Search Botulinum toxin is a protein and neurotoxin produced by the bacterium Clostridium botulinum. Botulinum toxin can cause botulism, a serious and life-threatening illness in humans and animals.[1][2] When introduced intravenously in monkeys, type A (Botox Cosmetic) of the toxin [citation exhibits an LD50 of 40–56 ng, type C1 around 32 ng, type D 3200 ng, and type E 88 ng needed]; these are some of the most potent neurotoxins known.[3] Popularly known by one of its trade names, Botox, it is used for various cosmetic and medical procedures. Botulinum can be absorbed from eyes, mucous membranes, respiratory tract or non-intact skin.[4] Contents [show] [edit] History Justinus Kerner described botulinum toxin as a "sausage poison" and "fatty poison",[5] because the bacterium that produces the toxin often caused poisoning by growing in improperly handled or prepared meat products. It was Kerner, a physician, who first conceived a possible therapeutic use of botulinum toxin and coined the name botulism (from Latin botulus meaning "sausage").
    [Show full text]
  • The Block of Shaker K Channels by -Conotoxin PVIIA Is State Dependent
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central The Block of Shaker K1 Channels by k-Conotoxin PVIIA Is State Dependent Heinrich Terlau,* Anna Boccaccio,* Baldomero M. Olivera,‡ and Franco Conti§ From the *Max-Planck-Institut für Experimentelle Medizin, 37075 Göttingen, Germany; ‡Department of Biology, University of Utah, Salt Lake City, Utah 84112; and §Istituto di Cibernetica e Biofisica, Consiglio Nazionale delle Ricerche, 16149 Genova, Italy abstract k-conotoxin PVIIA is the first conotoxin known to interact with voltage-gated potassium channels by inhibiting Shaker-mediated currents. We studied the mechanism of inhibition and concluded that PVIIA blocks the ion pore with a 1:1 stoichiometry and that binding to open or closed channels is very different. Open-channel properties are revealed by relaxations of partial block during step depolarizations, whereas double-pulse protocols 1 characterize the slower reequilibration of closed-channel binding. In 2.5 mM-[K ]o, the IC50 rises from a tonic value of z50 to z200 nM during openings at 0 mV, and it increases e-fold for about every 40-mV increase in volt- age. The change involves mainly the voltage dependence and a 20-fold increase at 0 mV of the rate of PVIIA disso- ciation, but also a fivefold increase of the association rate. PVIIA binding to Shaker D6-46 channels lacking N-type inactivation or to wild phenotypes appears similar, but inactivation partially protects the latter from open-channel 1 unblock. Raising [K ]o to 115 mM has little effect on open-channel binding, but increases almost 10-fold the tonic IC50 of PVIIA due to a decrease by the same factor of the toxin rate of association to closed channels.
    [Show full text]